Skip to main content
Caplight Logo









Genomind

Genomind

Private
King of Prussia, PennsylvaniaHealthcare & Life Scienceshttps://www.genomind.com

Last Round

Series D

Jan 29, 2021

Total Funding Raised

$20.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Genomind is a precision health company that specializes in mental healthcare, providing genetic testing and a biotechnology platform to aid in personalized treatment. The company's main offerings, including the Genomind Professional PGx Express and the direct-to-consumer Mental Health Map, analyze a patient's genetic makeup to provide insights on how they may respond to different medications for psychiatric conditions. This enables healthcare professionals to reduce trial-and-error in medication selection and develop more targeted treatment plans. Founded in 2009 by Dr. Ronald Dozoretz, Genomind aims to optimize the treatment experience for individuals and providers through actionable genetic insights and innovative health technology.

Sector

Healthcare & Life Sciences

Verticals

Mental Health, Precision Medicine, Biotechnology, Healthcare Analytics

Business Model

B2B2C

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

pharmacogenetic testingPGx testingmental health genetic testingpsychiatric pharmacogenomicsprecision medicineDNA test for medicationmedication response testclinical decision supportpharmacogenomicsdrug-gene interactionpersonalized medicinemedication managementgenetic testing for depressionEHR integrationDTC genetic testingcheek swab test

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genomind Comparables

Compare Genomind with similar companies based on industry and business-model similarity.

Genomind comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Myriad Genetics
86%
Castle Biosciences, Inc.
85%
OneOme
81%

Genomind Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DJan 29, 2021
Series BFeb 8, 2017
VC RoundSep 22, 2015
Series AApr 9, 2014

Key People

Founding team and executive leadership

Bill Brown

CEO

Executive Team

Maria Jose Springer

Chief Operating Officer, Chief Technology Officer

Executive Team

Genomind Investors

Notable investors and investment history

Genomind investors
InvestorRounds
Claritas CapitalSeries D, Series A, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2026

    Successfully treated over 500,000 patients.

Genomind Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Genomind Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersKing of Prussia, Pennsylvania
Employee Range60
Year Founded2009
Last FundingJan 29, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?